First Horizon Advisors Inc. Sells 1,329 Shares of Zoetis Inc. (NYSE:ZTS)

First Horizon Advisors Inc. reduced its position in Zoetis Inc. (NYSE:ZTS) by 2.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 46,329 shares of the company’s stock after selling 1,329 shares during the quarter. First Horizon Advisors Inc.’s holdings in Zoetis were worth $9,144,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Cary Street Partners Investment Advisory LLC raised its stake in Zoetis by 7.4% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 93,735 shares of the company’s stock valued at $16,308,000 after purchasing an additional 6,457 shares in the last quarter. Peak Financial Advisors LLC purchased a new stake in Zoetis in the fourth quarter valued at approximately $2,776,000. BLB&B Advisors LLC raised its stake in Zoetis by 1.9% in the third quarter. BLB&B Advisors LLC now owns 60,872 shares of the company’s stock valued at $10,591,000 after purchasing an additional 1,107 shares in the last quarter. Ninety One UK Ltd raised its stake in shares of Zoetis by 13.1% during the fourth quarter. Ninety One UK Ltd now owns 108,293 shares of the company’s stock worth $21,374,000 after acquiring an additional 12,537 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. raised its stake in shares of Zoetis by 10.9% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 183,564 shares of the company’s stock worth $36,230,000 after acquiring an additional 17,976 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have commented on ZTS. Piper Sandler reissued an “overweight” rating and set a $195.00 price target (down from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. The Goldman Sachs Group lifted their price target on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Stifel Nicolaus decreased their price target on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday. Barclays decreased their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 23rd. Finally, StockNews.com downgraded shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and an average price target of $216.13.

Insider Activity

In other news, EVP Roxanne Lagano sold 363 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $197.74, for a total transaction of $71,779.62. Following the completion of the transaction, the executive vice president now directly owns 20,417 shares in the company, valued at approximately $4,037,257.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last ninety days, insiders sold 2,209 shares of company stock worth $371,293. 0.16% of the stock is currently owned by insiders.

Zoetis Price Performance

ZTS traded down $0.16 during trading on Friday, reaching $167.07. 2,977,172 shares of the company traded hands, compared to its average volume of 3,178,449. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.00 and a current ratio of 3.36. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The firm has a fifty day simple moving average of $169.48 and a 200 day simple moving average of $178.89. The company has a market cap of $76.41 billion, a P/E ratio of 32.95, a PEG ratio of 2.48 and a beta of 0.86.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The business had revenue of $2.19 billion during the quarter, compared to analyst estimates of $2.14 billion. During the same period last year, the firm posted $1.31 EPS. The company’s revenue was up 9.5% on a year-over-year basis. On average, equities analysts forecast that Zoetis Inc. will post 5.78 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.03%. Zoetis’s dividend payout ratio is currently 34.12%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.